首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
【24h】

In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

机译:奎奴普丁/达福普汀和较新的喹诺酮类药物与庆大霉素联用对粪肠球菌和粪肠球菌耐药菌株的体外活性。

获取原文
获取原文并翻译 | 示例
       

摘要

In a study designed to obtain data on compounds active against enterococci, the minimum inhibitory concentrations (MICs) of quinupristin/dalfopristin (RP 59500) and the novel quinolones DU-6859a, trovafloxacin, levofloxacin, and sparfloxacin were determined for 122 Enterococcus faecalis and seven Enterococcus faecium isolates. In addition, 15 Enterococcus faecalis isolates resistant to gentamicin, DU-6859a, and trovafloxacin were exposed over time to combinations of DU-6859a plus gentamicin and trovafloxacin plus gentamicin. DU-6859a and trovafloxacin were found to be the most active compounds against Enterococcus faecalis and DU-6859a and RP 59500 against Enterococcus faecium. Synergy between either DU-6859a or trovafloxacin and gentamicin was observed with 27 to 35% of the isolates. It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin.
机译:在一项旨在获取对肠球菌具有活性的化合物的数据的研究中,确定了122种粪便肠球菌和7种喹诺普林/达福普汀和新型喹诺酮DU-6859a,曲伐沙星,左氧氟沙星和司巴沙星的最低抑菌浓度(MIC)。粪肠球菌分离株。此外,随着时间的流逝,将15种对庆大霉素,DU-6859a和曲伐沙星耐药的粪肠球菌分离株暴露于DU-6859a加庆大霉素和曲伐沙星加庆大霉素的组合。发现DU-6859a和trovafloxacin是对粪肠球菌最具活性的化合物,而DU-6859a和RP 59500是对粪肠球菌最具活性的化合物。观察到DU-6859a或曲伐沙星与庆大霉素之间的协同作用,其中分离株占27%至35%。结论是,DU-6859a和曲伐沙星对肠球菌非常有效,尤其是与庆大霉素合用时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号